Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease

Published:2024-09-15 Issue:18 Volume:63 Page:2491-2497
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ishikawa Toru¹,Terai Nanako²,Sato Ryo¹,Jimbo Ryo¹,Kobayashi Yuji¹,Sato Toshifumi¹,Iwanaga Akito¹,Sano Tomoe¹,Yokoyama Junji¹,Honma Terasu¹

Affiliation:

1. Department of Gastroenterology, Saiseikai Niigata Hospital, Japan

2. Department of Radiographer, Saiseikai Niigata Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/63/18/63_3259-23/_pdf

Reference20 articles.

1. 1. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 10: 284-296, 2022.

2. 2. Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 56: 951-963, 2021.

3. 3. Takahashi H, Kessoku T, Kawanaka M, et al. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatol Commun 6: 120-132, 2022.

4. 4. Ishikawa T, Imai M, Endo S, et al. Clinical efficacy of an SGLT2 inhibitor in type 2 diabetes complicated by nonalcoholic fatty liver disease and changes in body composition. Gut and Gastroenterology 3: 1-6, 2020.

5. 5. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 384: 1113-1124, 2021.